Abstract
Soft tissue sarcomas (STSs) represent a rare and heterogeneous group of solid tumors derived from mesenchymal progenitors and account for 1% of all adult malignancies. Although in the last decade anthracycline-based chemotherapy single agent or in combination has been able to improve clinical benefits, prognosis is still poor, and STSs represent an important unmet medical need.
According to major national and international guidelines, the optimal therapeutic strategy of all soft tissue sarcoma (STS) patients should be discussed within multidisciplinary teams.
A correct histopathological diagnosis is crucial, because the medical and surgical treatment depends on the different histology.
For this reason, in most cases, a biopsy reviewed by expert pathologist is needed to define the correct therapeutic procedure.
Continuous advances in cancer genetics and genomics have contributed to change management paradigms of STSs as it occurred for other solid tumors. Several treatments have been recently developed with the specific aim of targeting different cell pathways and immune-checkpoints that have been recognized to drive tumor progression.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.
Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95–104.
Judson I, Verweij J, Gelderblom H, Hartmann JT, Schöffski P, Blay JY, Kerst JM, Sufliarsky J, Whelan J, Hohenberger P, Krarup-Hansen A, Alcindor T, Marreaud S, Litière S, Hermans C, Fisher C, Hogendoorn PC, des Tos AP, van der Graaf WT, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15(4):415–23.
Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM classification of malignant tumours, 8th edn. Oxford: Wiley 2016.
Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17:671–80.
Haas RL, Gronchi A, van de Sande MAJ, et al. Perioperative management of extremity soft tissue sarcomas. J Clin Oncol. 2018;36:118–24.
Neuwirth MG, Song Y, Sinnamon AJ, et al. Isolated limb perfusion and infusion for extremity soft tissue sarcoma: a contemporary systematic review and meta-analysis. Ann Surg Oncol. 2017;24:3803–10.
Rizzo A, Nannini M, Astolfi A, et al. Impact of chemotherapy in the adjuvant setting of early stage uterine leiomyosarcoma: a systematic review and updated meta-analysis. Cancers (Basel). 2020;12(7):1899. Published 2020 Jul 14. https://doi.org/10.3390/cancers12071899.
MacNeill AJ, Gronchi A, Miceli R, et al. Postoperative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the transatlantic RPS working group. Ann Surg. 2018;267(5):959–64.
Marulli G, Mammana M, Comacchio G, et al. Survival and prognostic factors following pulmonary metastasectomy for sarcoma. J Thorac Dis. 2017;9:S1305–15.
Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203.
O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–41.
Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48–53.
Albertsmeier M, Rauch A, Roeder F, et al. External beam radiation therapy for resectable soft tissue sarcoma: a systematic review and meta-analysis. Ann Surg Oncol. 2018;25(3):754–67.
Naghavi AO, Fernandez DC, Mesko N, et al. American Brachytherapy Society consensus statement for soft tissue sarcoma brachytherapy. Brachytherapy. 2017;16:466–89.
Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15:1667–72.
Gronchi A, Frustaci S, Mercuri M, et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol. 2012;30:850–6.
Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017;18:812–22.
Rizzo A, Nannini M, Astolfi A, Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. Cancers (Basel). 2020;12(7):1899. https://doi.org/10.3390/cancers12071899. PMID: 32674439.
Sarcoma Meta-analysis C. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database Syst Rev. 2000:CD001419.
Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–47.
Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.
Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Onol. 2012;13:1045–54.
Napolitano A, Mazzocca A, Spalato Ceruso M, et al. Recent advances in desmoid tumor therapy. Cancers (Basel). 2020;12(8):2135. Published 2020 Aug 1. https://doi.org/10.3390/cancers12082135.
Benjamin RS, Wiernik PH, Bachur NR. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol. 1975;1:63–76.
Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014;15:415–23.
Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2015;15:415–23.
Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1089–103.
Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1397–410.
Cannella R, Tabone E, Porrello G, et al. Assessment of morphological CT imaging features for the prediction of risk stratification, mutations, and prognosis of gastrointestinal stromal tumors [published online ahead of print, 2021 Apr 21]. Eur Radiol. 2021;10.1007/s00330-021-07961-3. https://doi.org/10.1007/s00330-021-07961-3.
Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17:1213–20.
Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755–63.
Demetri GD, von Mehren M, Jones RL, et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol. 2016;34:786–93.
Schoffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016;387:1629–37.
van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.
Napolitano A, Mazzocca A, Spalato Ceruso M, Recent Advances in Desmoid Tumor Therapy. Cancers (Basel). 2020;12(8):2135. https://doi.org/10.3390/cancers12082135. PMID: 32752153.
Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002;20:3586–91.
Badalamenti G, Messina C, De Luca I, Musso E, Casarin A, Incorvaia L. Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. Radiol Med. 2019;124(4):259–65. https://doi.org/10.1007/s11547-018-0883-6.
Butrynski JE, D'Adamo DR, Hornick JL, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010;363:1727–33.
Badalamenti G, Incorvaia L, Messina C, et al. One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients [published correction appears in Support Care Cancer. 2019 May 14]. Support Care Cancer. 2019;27(9):3593–7. https://doi.org/10.1007/s00520-019-4645-3.
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18:1493–501.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Badalamenti, G., Vincenzi, B., Cani, M., Incorvaia, L. (2021). Soft Tissue Sarcomas (STS). In: Russo, A., Peeters, M., Incorvaia, L., Rolfo, C. (eds) Practical Medical Oncology Textbook. UNIPA Springer Series. Springer, Cham. https://doi.org/10.1007/978-3-030-56051-5_58
Download citation
DOI: https://doi.org/10.1007/978-3-030-56051-5_58
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-56050-8
Online ISBN: 978-3-030-56051-5
eBook Packages: MedicineMedicine (R0)